Invoke Capital Partners was founded by Dr Mike Lynch, members of the senior management team from Autonomy, and a group of technology experts, with access to $1bn in capital. Invoke is focused on maximizing the potential of European fundamental technology by using its unique expertise and repositioning experience to rapidly scale them across multiple markets. It is the only investment team in Europe with a dedicated, in-house R&D division, based in Cambridge, UK. The Invoke team has grown multiple technology businesses with particular expertise and experience in science and technology allowing them to identify and develop core technologies in areas including genomics, security, pattern recognition, signal processing and big data.

Invoke Capital

Endeavour Vision is a private equity firm investing in growth-stage MedTech and digital health companies. The company invests in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to health systems. Endeavour Vision team offers strategic and operational expertise and extensive international experience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Vertiflex (acquired by Boston Scientific in 2019), Medartis (IPO on SIX in Q1 2018), and Symetis (acquired by Boston Scientific in 2017).  Endeavour Vision’s offices are located in Geneva, Switzerland, and Minneapolis, U.S.

Endeavour Vision

Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007. Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technical expertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services. Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.

Swisscom Ventures

Reference Capital has built the ecosystem needed to find, track and access best-in-class Venture Funds that will drive outperformance for our clients.  We provide investment advisory services to institutional investors, including some of the most influential industrial families, foundations, pensions, private clients, corporate and government entities.  Our mission is to provide our clients unparalleled access to the most coveted investment opportunities in venture capital, with meaningful exposure to the emerging generation of technology leaders.

Reference Capital SA

Balderton Capital is a Venture Capital Investor that supports technology businesses. They support Founders at every stage of their journey. They provide advice, introduce portfolio leaders to professional service providers, and invite portfolio leaders to workshops and community events where they can meet one another.

Balderton Capital

360 Capital is a Venture Capital firm investing in early stage, innovative deeptech & digital enterprises across Europe. The firm has a 20-year track record of supporting talented tech entrepreneurs in developing ambitious & disruptive companies in a variety of sectors. Led by a diverse and experienced team of professionals located in Paris and Milan, 360 Capital has €400M of assets under management and an active portfolio of over 50 companies. A few examples from our current portfolio include Alsid, Earthcube, Exotec, Arbe Robotics, Sophia Genetics, Le Slip Français and Tediber.  Find out more on our website!

360 Capital

Alychlo is a family investment company of entrepreneurs who invest to make companies better and to give back to society.

Alychlo

Generation Investment Management is dedicated to investing, integrated sustainability research, and client alignment. The company believes the interests of shareholders, over time, will be best served by companies that improve financial returns by managing economic, social, and environmental performance. It also builds a global research platform to integrate sustainability research into fundamental financial analysis. The company's investment team was founded by bringing together investment analysts with leaders from the sustainability research field. Generation's investment approach is based on the conviction that sustainability risks and opportunities directly affect long-term business profitability.

Generation Investment Management

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primary investments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.  Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Idinvest Partners

aMoon is a leading healthtech & life sciences venture fund founded by Marius Nacht and Dr. Yair Schindel. Their team is passionate about building successful businesses and helping biopharma, digital health and medical technology companies realize their potential. They partner with management teams who use technology and cutting-edge science to accelerate cures for the world’s most life-threatening conditions and those providing solutions for global healthcare’s biggest cost drivers.

aMoon Fund

Credit Suisse Group is a financial services company that advises clients in all aspects of finance. Credit Suisse pursues a client-focused integrated bank strategy, focusing on complex client needs and value-adding businesses, leveraging the global expertise of our three divisions and reporting segments, Private Banking, Investment Banking, and Asset Management. It is their vision to become the world's premier and most admired bank, renowned for their expertise in private banking, investment banking, and asset management, and value for their advice, innovation, and execution. Their mission is to set new standards in partnering with their clients and providing them with innovative, integrated financial solutions. As a global bank serving clients in every region of the world, cultural diversity is essential to its success. They strive to create an open, respectful workplace that encourages people to work together and with their clients to deliver superior products, services, and results and support the success and prosperity of all their stakeholders.

Credit Suisse

Founded in Geneva in 1805, Pictet is today one of Switzerland's largest private banks, with assets under management and custody totalling USD 321 billion (CHF 349 / EUR 229) at the end of June 2009.

Pictet Private Equity Investors S.A.

Eurazeo is a private equity and venture capital firm that invests in SMEs and manages a diversified portfolio of assets. With its expertise in private equity, real estate, and private debt, the group supports companies of all sizes in their development commitment through the commitment of its 235 professionals. It provides companies with the necessary investments needed to realize their growth potential. The firm was founded in 1969 and is based in Paris, Ile-de-France, France.

Eurazeo

Famille C Venture is an investment structure of the Courtin family, founder and owner of Clarins.

Famillie C (Clarins Family)

Hitachi Ventures invests in innovative companies that address society’s key technological challenges in areas like IT, industrial automation (robotics, sensor technology and IoT), cloud services (data management, cybersecurity), mobility (autonomous driving, mobility services, smart infrastructure and security services), energy, smart medicine (AI for digital imaging, smart diagnostics, remote care), smart city, smart infrastructure and more.  With our first fund of USD 150M, we invest in Series A/B/C rounds in globally leading startups. From our offices in Munich, Germany, and Boston, USA, we work tirelessly to develop close ties and effective collaboration with leading innovative technology hubs and like-minded co-investors. Hitachi intends to leverage its strong position in multiple global technology markets, its expertise and network to support and promote Hitachi Ventures portfolio companies.

Hitachi Ventures

Era Funding Administration is an investment firm.

Era Funding Administration

SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The SOPHiA DDM™ Platform and related solutions, products and services are currently used by more than 780 hospital, laboratory and biopharma institutions globally.

<div>SOPHiA GENETICS is a bioinformatics company providing genomic and radiomic analysis services to hospitals, laboratories, and biopharma institutions. Its cloud-based SaaS analytics platform, SOPHiA DDM, facilitates insights from complex multimodal datasets across various disease areas, such as oncology, rare diseases, infectious diseases, cardiology, neurology, and metabolism. Using ML and patented algorithms, it calls, annotates, and pre-classifies variants from raw next-gen sequencing data. The platform evolves with ongoing data analysis, improving over time.</div>

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

SOPHiA GENETICS Reports Third Quarter 2024 Results

AstraZeneca

To accelerate the global rollout of a liquid biopsy test, MSK-ACCESS, powered by SOPHiA DDM, a genomic analysis platform.

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Microsoft

To develop a whole-genome sequencing (WGS) analytical solution to offer streamlined and scalable insights to healthcare providers.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

NVIDIA

To bring a streamlined and scalable whole genome sequencing (WGS) analytical solution to healthcare institutions

PMV Pharmaceuticals

Unilabs

To deploy SOPHiA GENETICS' platform to support ovarian cancer diagnostics in Switzerland

Unilabs deploys SOPHiA GENETICS' platform to support ovarian cancer diagnostics in Switzerland

Agilent Technologies

To offer a comprehensive solution for cancer analysis by integrating Agilent's research-use-only SureSelect Cancer Comprehensive Genomic Profiling (CGP) Assay Kit.

Qiagen

To expand the use of QIAGEN's NGS kits by integrating them with SOPHiA GENETICS' data analytics platform, enabling customers to access a wider range of precision diagnostics and research insights.

SOPHiA GENETICS SA is partnering with AstraZeneca (LSE/STO/Nasdaq: AZN) to apply their multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

SaaS (Software-as-a-Service) companies aggregating and analyzing biomedical data with the help of AI to generate insights across the drug development pipeline.

Azure

Collaborating to enable a multimodal data curation, development, and deployment. In turn, the Microsoft Azure-powered SOPHiA DDM™ Platform is expected to increase the standard of care for patients, by delivering advanced outcomes for precision medicine.

GE Healthcare

Collaborating on opportunities in the healthcare market, including various initiatives and projects in the fields of digital oncology and radiogenomic analysis.

GE Healthcare has announced collaborations with SOPHiA GENETIC as part of its vision to advance care and ultimately improve outcomes for cancer patients.

GE Healthcare and SOPHiA GENETICS collaborate to match treatments to multimodal patient data and cancer type

Hitachi

Two companies  will advance data-driven precision medicine through global commercial expansion and development of Hitachi’s digital healthcare solutions and the SOPHiA DDM™ Platform.

<div>
 
 SOPHiA GENETICS is a bioinformatics company providing genomic and radiomic analysis services to hospitals, laboratories, and biopharma institutions. Its cloud-based SaaS analytics platform, SOPHiA DDM, facilitates insights from complex multimodal datasets across various disease areas, such as oncology, rare diseases, infectious diseases, cardiology, neurology, and metabolism. Using ML and patented algorithms, it calls, annotates, and pre-classifies variants from raw next-gen sequencing data. The platform evolves with ongoing data analysis, improving over time.
 
 
 Customers maintain control over their samples and data, using the SOPHiA DDM platform to analyze data and exchange insights, contributing to a shared knowledge pool. As of October 2023, the platform had supported the analysis of over 1.2 million genomic profiles. Additionally, the company provides genomics mutation interpretation software, Alamut, offering advanced analytics for more comprehensive genomic data interpretation. SOPHiA GENETICS follows a B2B model, serving the clinical and biopharma markets.
 
 
 Key partnerships and customers
 
 
 As of October 2023, SOPHiA GENETICS had partnerships with 750+ institutions across 72 countries.
 
 
 Funding and financials
 
 
 SOPHiA GENETICS went public on the Nasdaq in 2021, floating at USD 1.1 billion under the ticker symbol &quot;SOPH.&quot; For 2022, the company reported a net loss of USD 87.4 million (up 19% YoY), while revenue amounted to USD 47.6 million (up 18% YoY).
 
</div>

<div>
 
 Praxis Precision Medicines is a clinical-stage biopharmaceutical company that develops precision medicine for central nervous system disorders based on neuronal imbalance caused by genetic mutations.
 
 
 The company has four clinical-stage product candidates in its pipeline for treating disorders such as depression, epilepsy, movement disorders, and pain syndromes. The company&rsquo;s drug candidates include 1) PRAX-944, which is an inhibitor for essential tremor disorder linked to Parkinson&rsquo;s disease and is set to begin Phase 3 in mid-2023, 2) PRAX-222 in Phase 2 of clinical trials targets the SCN2A gene most commonly associated with early-onset epilepsy, 3) PRAX-562 was designed to block persistent sodium for patients suffering from rare diseases such as headache disorders and severe seizures and completed Phase 1 of clinical trials, and 4) PRAX-628 in Phase 2 clinical trials for treating focal epilepsy that originates in one side or area of the brain and affects one side of the body. Additionally, the firm has six pre-clinical drug candidates.
 
 
 Funding and financials
 
 
 The company went public in October 2020, trading on the Nasdaq Global Select Market under the ticker symbol &ldquo;PRAX&rdquo;. 
 <a href="https://sp-edge.com/updates/19453">
 In June 2023 
 </a>
 , the company announced an underwritten public offering of its common shares and pre-funded warrants, to raise approximately USD 59.1 million. The capital raised was used to support the company&rsquo;s ongoing operations and strategic initiatives, furthering the development of its pipeline and potential future endeavors.
 
 
 For the year 
 <a href="https://sp-edge.com/updates/16211">
 2022
 </a>
 , net losses increased by 28% YoY to USD 214 million arising from a significant increase in R&amp;D expense (up by 29% YoY). For the six months ended June 2023, the company is yet to generate revenue from drugs, however received collaboration revenue of USD 1.5 million. Further, it reported a decline in net loss by 43.0% YoY to USD 34.3 million. Its cash and cash equivalent as of June 2023 was at USD 124.3 million, compared to USD 61.6 million in December 2022, which the company believes will be adequate to fund operations till Q1 2025. 
 
</div>

Praxis Precision Medicines

<div>
 
 Mirati Therapeutics is a commercial-stage biotechnology company developing oncology-targeted therapies to address KRAS mutations present in 25% of tumors, including lung, colorectal and pancreatic cancers. Mirati&rsquo;s lead product KRAZATI (adagrasib/ MRTX849) is an oral&nbsp; KRASG12C inhibitor approved in 2022 for certain non-small cell lung cancers.The company also has sitravatinib, a multi-kinase inhibitor, in Phase 3 trials for non-small cell lung cancer in combination with a Bristol-Myers Squibb checkpoint inhibitor.
 
 
 
 
 Additionally, Mirati is advancing multiple early-stage programs including KRAS G12D inhibitor MRTX1133 for pancreatic and colorectal cancers, which entered Phase 1 in 2023, as well as a synthetic lethal inhibitor MRTX1719. In December 2022, the company submitted an IND application for MRTX1133, a potent and selective KRAS G12D inhibitor, which was cleared by the FDA in January 2023. 
 
 
 Key partnerships and customers
 
 
 
 
 Mirati has multiple partnerships with leading biopharma companies to advance its pipeline, including discovery collaborations with Pfizer and clinical collaborations with Novartis, Boehringer Ingelheim, and 
 <a href="https://sp-edge.com/updates/14345">
 Incyte
 </a>
 . The company also has licensing agreements with BeiGene for sitravatinib and Zai Lab for MRTX849 in certain Asian markets.
 
 
 
 
 
 Funding and Financials
 
 
 
 
 The company went public in June 2013 to trade on Nasdaq under the ticker symbol &ldquo;MRTX&rdquo;. In August 2023, the company closed an 
 <a href="https://sp-edge.com/updates/20988">
 underwritten public offering
 </a>
 at USD 345 million. The new funds were used towards drug development and leadership expansion.&nbsp;
 
 
 
 
 <a href="https://sp-edge.com/updates/16725">
 For the year 2022 
 </a>
 , the firm's net losses increased to USD 740.9 million from USD 581.8 million. Net product revenue for the full year amounted to USD 0.7 million arising from the sale of KRAZATI, which received FDA approval for its commercial launch in December 2022. 
 
</div>

Mirati Therapeutics

<div>
 
 Tvardi Therapeutics is a clinical-stage biotechnology company developing precision medicine for different cancers, chronic inflammatory diseases, and fibrotic diseases. The company&rsquo;s pipeline focuses on the development of small-molecule inhibitors of STAT3, a regulatory protein that allows cancer cells to evade the immune system and survive.
 
 
 The company&rsquo;s orally administered monotherapy and lead product, TTI-101, is in Phase 1 clinical trials for patients with advanced solid tumors who have failed all other lines of therapy. Additionally, the drug is in preclinical trials for treating fibrosis and inflammation. The company is also developing TTI-102, a next-generation STAT3 inhibitor that is structurally similar but chemically different from TTI-101.&nbsp;
 
 
 Founded in 2017, the Texas-based company closed a Series B funding round in June 2021, which brought total funding to USD 81 million and the proceeds will be used to advance Tvardi&rsquo;s drug candidates through its clinical data readouts in mid-stage trials for cancer and fibrosis.
 
</div>

Tvardi Therapeutics

<div>
 
 Tango Therapeutics is a clinical-stage biotech company developing precision oncology therapies targeting synthetic lethality in cancer which leads to cell death. Its discovery platform identifies novel targets to develop drugs focused on: 1) countering tumor suppressor gene loss to help the immune system recognize and kill cancer cells, and 2) reversing cancer cell evasion of the immune system.
 
 
 
 
 Tango has five pipeline programs, including lead candidate TNG908, an inhibitor for multiple cancer indicators. The FDA approved TNG908's IND in January 2022 and granted it Orphan Drug Designation. TNG908 is in Phase I/II trials, with preliminary efficacy data expected in H1 2023. Tango also plans to file INDs for TNG260 (STK11 mutant cancers) and TNG348 (BRCA1/2-mutant cancers). In 
 <a href="https://www.globenewswire.com/news-release/2023/01/25/2595034/0/en/Tango-Therapeutics-Announces-FDA-Clearance-of-Investigational-New-Drug-Application-for-TNG462-Provides-Additional-Business-Updates.html">
 January 2023
 </a>
 , the FDA cleared the IND for TNG462, a next-gen PRMT5 inhibitor for cancers with MTAP deletion.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 
 Outside its pipeline, the company also entered into a collaborative partnership with big pharma Gilead Sciences Inc., in October 2018 which was later expanded for two years in August 2020 to identify new immune evasion targets.
 
 
 
 
 Funding and financials&nbsp;
 
 
 
 
 
 Tango went public in August 2021 via a SPAC deal, trading on Nasdaq under the ticker symbol &ldquo;TNGX&rdquo;, and the company received gross proceeds of USD 353 million. In August 2023, the company raised USD 80 million via a 
 <a href="https://sp-edge.com/updates/20955">
 private placement
 </a>
 , which was led by Nextech. The new funds were used toward expanding its TNG908 and TNG462 PRMT5 programs to various other indications.
 
 
 
 
 Tango has not yet generated any drug sales and does not expect to do so for several years. However, for the full-year the company reported collaboration revenue of USD 24.9 million (down 4.42% YoY) and a net loss of USD 108.2 million (up 85.9% YoY).
 
 
 
</div>

Tango Therapeutics

<div>
 
 IDEAYA Biosciences is a clinical-stage biotech developing precision cancer therapies based on synthetic lethality - when specific gene mutations pair to cause cell death. The company also studies combining synthetic lethality with immunotherapies and DNA damage to enhance treatment efficacy. While current drugs target limited mutations like BRCA1/2, IDEAYA aims to treat broader genetic subpopulations.&nbsp;
 
 
 
 
 Its pipeline includes synthetic lethality-driven precision medicines across four potential first-in-class clinical-stage product candidates. Of these, the company owns/controls commercial rights of the three most-advanced of these product candidates: darovasertib, IDE397, and IDE161. As of May 2024, the company was also advancing Werner Helicase program for which a development candidate has been selected in collaboration with GlaxoSmithKline, and, subject to investigational new drug-, or IND-, enabling studies, are targeting an IND in 2024. In addition. the company also works on multiple earlier-stage preclinical programs. 
 
 
 By targeting specific genetic drivers, IDEAYA advances precision oncology using synthetic lethality approaches. The company is focused on developing novel targeted therapies for patient populations with high unmet need and limited treatment options.&nbsp;&nbsp;
 
 
 In December 2023, IDEAYA Biosciences teamed up with Gilead Sciences to test the combination of IDE397 and Trodelvy in a Phase I clinical trial for MTAP-deletion bladder cancer.
 
 
 
 
 Key partnerships and customers
 
 
 
 
 The company collaborates with pharmaceutical partners to advance its pipeline, including a strategic partnership with GSK in June 2020. The collaboration with GSK covers co-development and commercialization of two synthetic lethality programs. IDEAYA received USD 100 million upfront and USD 20 million in a direct private placement through the GSK deal. In June 2022, IDEAYA announced it would co-develop its Pol Theta candidate with GSK, with a Phase 1 trial starting in the first half of 2023.&nbsp;
 
 
 
 
 IDEAYA also holds an exclusive license from Novartis for LXS196 (IDE196), a PKC inhibitor for metastatic uveal melanoma. Additionally, the company is exploring IDE196 combinations with Pfizer and its potential in other rare skin diseases. In July 2022, IDEAYA signed an agreement with Amgen to evaluate IDE397 with Amgen's AMG 193 in solid tumors. Strategic pharma partnerships help advance and expand IDEAYA's pipeline of synthetic lethality precision oncology programs.
 
 
 
 
 Funding and financials
 
 
 
 
 
 The company was listed on the Nasdaq Global Select Market under the ticker symbol &ldquo;IDYA&rdquo; in May 2019, raising USD 50 million via an initial public offering. In September 2022, the company raised USD 92 million.&nbsp;
 
 
 
 
 For 2022, the company reported a net loss of USD 58.7 million (up 17.9% YoY) while collaboration revenue was USD 50.9 million (up 82.3% YoY). 
 
 
 On October 24, 2023, IDEAYA Biosciences priced an underwritten public offering of 5 million shares of common stock and pre-funded warrants to purchase 319,150 shares of common stock. The common stock offered was priced at USD 23.50 per share, while the exercise price of a pre-funded warrant was USD 0.0001. The offering was expected to bring in approximately USD 125 million in gross proceeds.
 
 
 
</div>

IDEAYA Biosciences

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

Some companies leverage AI/ML to develop tailored medication

Considers individual variability in genes, environment, and lifestyle for each person

Genomics is used across all the segments of precision medicine from diagnostic solutions to treatments

AI/ML analyzes genomic data to find drug targets, predict disease progression, and treatment response

ANALYST_QUICK_TAKE

PROMINENT_CATEGORY

<div>
 SOPHiA GENETICS has received the CE marking under the EU's In Vitro Diagnostic Regulation (IVDR) for its SOPHiA DDM Platform, enabling its use in patient diagnostics across the EU and other markets that recognize this certification.
 The platform uses SOPHiA GENETICS' AI algorithms and includes five existing CE-IVD applications, a global network of partners, and has processed over 1.7 million genomic profiles. It uses next-generation sequencing (NGS) to analyze raw data and provide reliable HRD results for personalized oncology treatment planning.
 
</div> Analyst QuickTake: 
 SOPHiA DDM (Data-driven Medicine) is a cloud-based platform that provides advanced data analysis solutions for healthcare institutions. The platform uses AI and ML to analyze complex genomic data, supporting a range of applications including oncology, hereditary disorders, and infectious diseases. Initially launched as a research tool for hospitals and research labs, the platform has expanded its capabilities, with its most recent addition being a residual acute myeloid (RAM) application, which was launched in <a href="https: 
//sp-edge.com/updates/30716"> June 2024 </a> to strengthen the company's oncology portfolio with measurable residual disease (MRD) testing capabilities.

SOPHiA GENETICS

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless